Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas

Leuk Lymphoma. 2022 Jan;63(1):231-234. doi: 10.1080/10428194.2021.1975190. Epub 2021 Sep 6.

Authors

Tamer Othman¹, Benjamin N Moskoff¹, Naseem Esteghamat¹, Rasmus T Hoeg², Aaron S Rosenberg¹, Brian A Jonas², Mehrdad Abedi², Carol Richman¹, Joseph M Tuscano¹

Affiliations

¹ University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
² Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USA.

PMID: 34486920
DOI: 10.1080/10428194.2021.1975190

No abstract available

Publication types

Letter

MeSH terms

Antilymphocyte Serum
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma* / diagnosis
Lymphoma* / therapy
Transplantation Conditioning

Substances

Antilymphocyte Serum